News | March 21, 2024
Bristol Myers Squibb completes acquisition of Karuna Therapeutics
KarXT, Karuna’s lead asset, is a potential first-in-class treatment for Schizophrenia
KarXT, Karuna’s lead asset, is a potential first-in-class treatment for Schizophrenia
To accelerate the development of next-generation radioconjugates to treat cancer
Ukrainian marketing approvals for paclitaxel, oxaliplatin and irinotecan mark a significant milestone in the company’s global expansion strategy
Versavo is the first Dr. Reddy's biosimilar product to be approved and launched in the UK
The first and only oral androgen deprivation therapy treatment for men with advanced prostate cancer
New facility includes 20KL of single use drug substance capacity coupled with drug product filling capacity of up to one million vials per day
The drug will target specific genetic mutations prevalent in certain types of cancers
Acquisition broadens oncology pipeline with a portfolio of novel T-cell engagers including HPN328 (MK-6070), an investigational delta-like ligand 3 (DLL3) targeting T-cell engager
India is contributing 13% to the global asthma burden and a disproportionate 43% of the global asthma deaths.
CRESEMBA receives seven years and six months of US market exclusivity for these pediatric indications
Subscribe To Our Newsletter & Stay Updated
